BGLC - Company ID 0001737523
The table below shows BioNexus Gene Lab Corp's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.42M | $9.51M | $9.77M | $10.93M | $13.36M | $11.39M |
| Cost of revenue | $6.34M | $8.22M | $8.44M | $9.67M | $11.10M | $9.67M |
| Gross profit | $1.09M | $1.29M | $1.33M | $1.26M | $2.27M | $1.72M |
| R&D | $50.67K | $47.51K | $54.98K | - | - | - |
BioNexus Gene Lab Corp reported annual revenue of $7.42M for fiscal year 2025. That is down 21.9% from $9.51M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $212.33K (FY 2018) to $7.42M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $1.54M |
| $1.83M |
| $2.44M |
| $1.73M |
| $1.28M |
| $1.33M |
| Operating income | -$2.97M | -$1.57M | -$2.59M | -$291.18K | $1.06M | $1.27M |
| Income tax | $0.00 | -$3.49K | -$21.53K | -$52.31K | -$291.28K | - |
| Net income | -$2.98M | -$1.60M | -$2.63M | -$355.97K | $751.57K | $1.09M |
| EPS (diluted) | - | -$0.09 | -$0.17 | - | - | - |